Notwithstanding that the majority of MTC cells overexpress the cholecystokinin-2 receptor (CCK-2R) in high density, there is currently no CCK-2R-targeted compound available that shows promising pharmacokinetics and bears the possibility of 18F-labeling. Here, CCKBR is linked to medullary thyroid gland carcinoma.